ProLynx Raises $70 Million to Develop Extended-Release Obesity Drugs with Monthly and Quarterly Dosing
核心洞察
ProLynx (搜索), a biotechnology startup founded in 2010, has secured $70 million in Series A funding to develop obesity (搜索) drugs that require less frequent dosing than current weekly injections.
The company's proprietary technology uses tunable chemical linkers to extend drug half-life, potentially enabling monthly or quarterly dosing of GLP-1 (搜索) receptor agonists and other weight-loss medications.
ProLynx (搜索) plans to develop a once-monthly version of semaglutide and other longer-acting formulations to address patient adherence issues and side effects associated with current weekly obesity (搜索) treatments.
Biotechnology startup ProLynx (搜索) has raised $70 million in Series A funding to develop obesity (搜索) drugs that require significantly less frequent dosing than existing weekly medications. The Emeryville, California-based company announced the financing round Thursday, with co-leadership from healthcare-focused venture capital firms 5AM Ventures (搜索), OrbiMed (搜索), and Monograph Capital (搜索).
Extended-Release Technology Platform
ProLynx (搜索)'s approach centers on proprietary chemical linkers that can extend the half-life of various drugs, including small molecules and antibodies. The technology creates what CEO Chris Boulton describes as "essentially a three-part molecule combining a microsphere hydrogel carrier attached to the drug of interest by a tunable release linker."
"These linkers can be tailored," Boulton explains. "They're like little clocks, and you can design how quickly you want them to degrade and release the active drug." The company believes it can extend drug half-life to 90 days or longer, a duration Boulton says is unmatched elsewhere in the industry.
Addressing Current Treatment Limitations
The company is targeting significant limitations in current obesity (搜索) treatments like Eli Lilly's Zepbound and Novo Nordisk's Wegovy, which require weekly injections and are associated with gastrointestinal side effects that can lead to treatment discontinuation.
"People can take a dose, and for the first couple of days afterwards they can feel pretty under the weather. Then by the end of the week, the food noise can be returning," says Boulton, who joined ProLynx (搜索) in November after working in obesity (搜索) and metabolic drug roles at Amgen, Sanofi, and AstraZeneca.
"Having a portfolio that is much longer... and then the ability to go to monthly and quarterly, really could solve a lot of these unmet needs and get patients to stay on therapy longer," Boulton adds.
Pipeline Development Strategy
ProLynx (搜索) plans to develop both "incretin" drugs that stimulate or mimic gut hormones and "non-incretin" therapies. The company's lead program involves creating a once-monthly version of semaglutide, the active ingredient in Novo Nordisk's Wegovy.
Behind the longer-acting semaglutide are formulations of a dual-acting GLP-1 (搜索)/GIPR (搜索) agonist and an amylin (搜索) drug, both targeting well-studied obesity (搜索) mechanisms, that could be dosed monthly or quarterly. Boulton indicates the company intends to leverage regulatory pathways that enable modified versions of existing medicines to reach market more quickly by borrowing from existing data.
Market Opportunity and Competition
The obesity (搜索) drug market represents a substantial opportunity, with combined sales of Lilly's Zepbound and Mounjaro making it the world's most lucrative medicine this year. Analysts project the market for these drugs could surpass $100 billion by 2030.
This potential has driven significant investment activity, with venture firms pouring at least $1 billion into metabolic disease drug startups in each of the last two years. Other companies including Camurus (搜索) and Ascendis Pharma are also working to extend dosing periods for weight-loss drugs, though most current efforts focus on weekly dosing.
Company Background
ProLynx (搜索) was founded in 2010 by Daniel Santi, a University of California, San Francisco professor who has cofounded multiple biotechs, and Gary Ashley, an industry veteran with more than 20 years of experience. The company has operated in stealth mode since its founding, originally targeting the extended-release technology for cancer applications.
The company has already demonstrated its platform's versatility by creating a long-acting version of a prodrug of the topoisomerase 1 (搜索) inhibitor SN-38, found in irinotecan and sacituzumab govitecan, which has entered clinical trials for rare central nervous system cancers (搜索).
Boulton views obesity (搜索) as "not just one condition, but multiple conditions," reflecting the company's approach to developing a diverse portfolio of longer-acting treatments. The company has not disclosed specific timelines for when its experimental obesity medicines will enter clinical testing.